|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FKBP9 |
Gene summary for FKBP9 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FKBP9 | Gene ID | 11328 |
| Gene name | FKBP prolyl isomerase 9 | |
| Gene Alias | FKBP60 | |
| Cytomap | 7p14.3 | |
| Gene Type | protein-coding | GO ID | GO:0000413 | UniProtAcc | A7YQ73 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11328 | FKBP9 | P22T-E | Human | Esophagus | ESCC | 1.03e-35 | 6.94e-01 | 0.1236 |
| 11328 | FKBP9 | P23T-E | Human | Esophagus | ESCC | 9.42e-07 | 3.90e-01 | 0.108 |
| 11328 | FKBP9 | P24T-E | Human | Esophagus | ESCC | 5.80e-14 | 2.86e-01 | 0.1287 |
| 11328 | FKBP9 | P26T-E | Human | Esophagus | ESCC | 3.01e-32 | 6.80e-01 | 0.1276 |
| 11328 | FKBP9 | P27T-E | Human | Esophagus | ESCC | 3.55e-40 | 9.53e-01 | 0.1055 |
| 11328 | FKBP9 | P28T-E | Human | Esophagus | ESCC | 2.26e-38 | 8.88e-01 | 0.1149 |
| 11328 | FKBP9 | P30T-E | Human | Esophagus | ESCC | 2.13e-23 | 8.65e-01 | 0.137 |
| 11328 | FKBP9 | P31T-E | Human | Esophagus | ESCC | 1.10e-45 | 7.49e-01 | 0.1251 |
| 11328 | FKBP9 | P32T-E | Human | Esophagus | ESCC | 2.92e-48 | 1.05e+00 | 0.1666 |
| 11328 | FKBP9 | P36T-E | Human | Esophagus | ESCC | 1.34e-12 | 5.99e-01 | 0.1187 |
| 11328 | FKBP9 | P37T-E | Human | Esophagus | ESCC | 3.01e-30 | 9.02e-01 | 0.1371 |
| 11328 | FKBP9 | P39T-E | Human | Esophagus | ESCC | 6.87e-03 | 2.39e-01 | 0.0894 |
| 11328 | FKBP9 | P40T-E | Human | Esophagus | ESCC | 8.19e-06 | 3.96e-01 | 0.109 |
| 11328 | FKBP9 | P42T-E | Human | Esophagus | ESCC | 1.61e-21 | 7.34e-01 | 0.1175 |
| 11328 | FKBP9 | P44T-E | Human | Esophagus | ESCC | 3.49e-15 | 5.59e-01 | 0.1096 |
| 11328 | FKBP9 | P47T-E | Human | Esophagus | ESCC | 1.05e-18 | 5.47e-01 | 0.1067 |
| 11328 | FKBP9 | P48T-E | Human | Esophagus | ESCC | 7.81e-20 | 3.28e-01 | 0.0959 |
| 11328 | FKBP9 | P49T-E | Human | Esophagus | ESCC | 3.29e-06 | 1.08e+00 | 0.1768 |
| 11328 | FKBP9 | P52T-E | Human | Esophagus | ESCC | 7.58e-26 | 6.80e-01 | 0.1555 |
| 11328 | FKBP9 | P54T-E | Human | Esophagus | ESCC | 4.06e-19 | 2.36e-01 | 0.0975 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006457 | Colorectum | AD | protein folding | 73/3918 | 212/18723 | 3.24e-06 | 9.10e-05 | 73 |
| GO:00064571 | Colorectum | SER | protein folding | 54/2897 | 212/18723 | 1.04e-04 | 2.18e-03 | 54 |
| GO:00064572 | Colorectum | MSS | protein folding | 71/3467 | 212/18723 | 1.25e-07 | 5.91e-06 | 71 |
| GO:00064574 | Colorectum | FAP | protein folding | 44/2622 | 212/18723 | 4.36e-03 | 2.98e-02 | 44 |
| GO:0006457110 | Esophagus | ESCC | protein folding | 163/8552 | 212/18723 | 1.13e-20 | 1.74e-18 | 163 |
| GO:001820816 | Esophagus | ESCC | peptidyl-proline modification | 46/8552 | 58/18723 | 1.59e-07 | 2.51e-06 | 46 |
| GO:000041313 | Esophagus | ESCC | protein peptidyl-prolyl isomerization | 32/8552 | 42/18723 | 5.52e-05 | 4.27e-04 | 32 |
| GO:00064577 | Liver | Cirrhotic | protein folding | 114/4634 | 212/18723 | 9.23e-20 | 2.31e-17 | 114 |
| GO:00182084 | Liver | Cirrhotic | peptidyl-proline modification | 26/4634 | 58/18723 | 6.65e-04 | 5.04e-03 | 26 |
| GO:00004132 | Liver | Cirrhotic | protein peptidyl-prolyl isomerization | 19/4634 | 42/18723 | 3.00e-03 | 1.71e-02 | 19 |
| GO:000645712 | Liver | HCC | protein folding | 160/7958 | 212/18723 | 1.07e-22 | 1.88e-20 | 160 |
| GO:001820811 | Liver | HCC | peptidyl-proline modification | 42/7958 | 58/18723 | 3.73e-06 | 4.85e-05 | 42 |
| GO:00004131 | Liver | HCC | protein peptidyl-prolyl isomerization | 31/7958 | 42/18723 | 3.83e-05 | 3.80e-04 | 31 |
| GO:000645718 | Oral cavity | OSCC | protein folding | 154/7305 | 212/18723 | 1.89e-23 | 4.60e-21 | 154 |
| GO:00182088 | Oral cavity | OSCC | peptidyl-proline modification | 42/7305 | 58/18723 | 2.49e-07 | 3.92e-06 | 42 |
| GO:00004134 | Oral cavity | OSCC | protein peptidyl-prolyl isomerization | 28/7305 | 42/18723 | 2.61e-04 | 1.67e-03 | 28 |
| GO:000645719 | Oral cavity | LP | protein folding | 125/4623 | 212/18723 | 1.62e-26 | 8.45e-24 | 125 |
| GO:001820815 | Oral cavity | LP | peptidyl-proline modification | 28/4623 | 58/18723 | 8.35e-05 | 1.07e-03 | 28 |
| GO:000041312 | Oral cavity | LP | protein peptidyl-prolyl isomerization | 22/4623 | 42/18723 | 1.04e-04 | 1.26e-03 | 22 |
| GO:0006457112 | Thyroid | PTC | protein folding | 137/5968 | 212/18723 | 8.29e-23 | 2.01e-20 | 137 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FKBP9 | SNV | Missense_Mutation | novel | c.1864G>C | p.Glu622Gln | p.E622Q | O95302 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AR-A2LE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | PD |
| FKBP9 | SNV | Missense_Mutation | c.966N>C | p.Glu322Asp | p.E322D | O95302 | protein_coding | tolerated(0.13) | benign(0.003) | TCGA-E9-A1NA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| FKBP9 | insertion | Frame_Shift_Ins | novel | c.659_660insCAGGAGGCAGGGGACC | p.Phe221ArgfsTer22 | p.F221Rfs*22 | O95302 | protein_coding | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| FKBP9 | insertion | Frame_Shift_Ins | novel | c.660_661insGGCACTGGAAGGG | p.Phe221GlyfsTer21 | p.F221Gfs*21 | O95302 | protein_coding | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| FKBP9 | SNV | Missense_Mutation | novel | c.551T>C | p.Val184Ala | p.V184A | O95302 | protein_coding | tolerated(0.05) | benign(0.345) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| FKBP9 | SNV | Missense_Mutation | c.1660N>C | p.Asp554His | p.D554H | O95302 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EK-A2H0-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| FKBP9 | SNV | Missense_Mutation | c.1660N>C | p.Asp554His | p.D554H | O95302 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-ZJ-A8QQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| FKBP9 | SNV | Missense_Mutation | novel | c.1034N>A | p.Gly345Asp | p.G345D | O95302 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| FKBP9 | SNV | Missense_Mutation | novel | c.695A>G | p.Asp232Gly | p.D232G | O95302 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FKBP9 | SNV | Missense_Mutation | c.1442N>A | p.Gly481Glu | p.G481E | O95302 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |